Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Jimenez Freddy A.

2. Date of Event Requiring Statement (MM/DD/YYYY) 1/1/2021

3. Issuer Name and Ticker or Trading Symbol

Celldex Therapeutics, Inc. [CLDX]

(Last) (First) (Middle)

C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___X___ Officer (give title below) _____ Other (specify below)
SVP & General Counsel /

(Street)

HAMPTON, NJ 08827

(City) (State) (Zip)

5. If Amendment, Date Original Filed(MM/DD/YYYY)

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Employee Stock Option (right to buy)	⁽¹⁾	3/1/2026	Common Stock	1400	$112.50	D
Employee Stock Option (right to buy)	⁽²⁾	6/8/2026	Common Stock	733	$70.80	D
Employee Stock Option (right to buy)	⁽³⁾	8/11/2026	Common Stock	266	$65.40	D
Employee Stock Option (right to buy)	⁽⁴⁾	6/15/2027	Common Stock	1666	$34.80	D
Employee Stock Option (right to buy)	⁽⁵⁾	6/13/2028	Common Stock	4166	$9.0165	D
Employee Stock Option (right to buy)	⁽⁶⁾	6/19/2029	Common Stock	20000	$2.78	D
Employee Stock Option (right to buy)	⁽⁷⁾	6/18/2030	Common Stock	36000	$10.38	D

Explanation of Responses:
(1)	The option became exercisable as to 25% of the shares on March 1, 2017 and the remaining shares vested quarterly (in equal amounts) over the subsequent 12 quarters. This option is currently fully vested.
(2)	The option became exercisable as to 25% of the shares on June 8, 2017 and the remaining shares vested quarterly (in equal amounts) over the subsequent 12 quarters. This option is currently fully vested
(3)	The option became exercisable as to 25% of the shares on August 11, 2017 and the remaining shares vested quarterly (in equal amounts) over the subsequent 12 quarters. This option is currently fully vested.
(4)	The option became exercisable as to 25% of the shares on June 15, 2018 and the remaining shares vest quarterly (in equal amounts) over the subsequent 12 quarters.
(5)	The option became exercisable as to 25% of the shares on June 13, 2019 and the remaining shares vest quarterly (in equal amounts) over the subsequent 12 quarters.
(6)	The option became exercisable as to 25% of the shares on June 19, 2020 and the remaining shares vest quarterly (in equal amounts) over the subsequent 12 quarters.
(7)	The option becomes exercisable as to 25% of the shares on June 18, 2021 and the remaining shares vest quarterly (in equal amounts) over the subsequent 12 quarters.

Remarks:
Exhibit List Exhibit 24 - Power of Attorney

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Jimenez Freddy A. C/O CELLDEX THERAPEUTICS, INC. 53 FRONTAGE ROAD, SUITE 220 HAMPTON, NJ 08827			SVP & General Counsel